BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38561690)

  • 1. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    Sheng M; Sun R; Fu J; Lu G
    BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
    Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
    Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
    Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y
    BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
    Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
    Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling.
    Navarro-Núñez L; Pollitt AY; Lowe K; Latif A; Nash GB; Watson SP
    Thromb Haemost; 2015 May; 113(5):1109-20. PubMed ID: 25694214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.
    Bianchi R; Fischer E; Yuen D; Ernst E; Ochsenbein AM; Chen L; Otto VI; Detmar M
    J Biol Chem; 2014 Jul; 289(30):21016-27. PubMed ID: 24907275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
    Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
    J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podoplanin-positive periarteriolar stromal cells promote megakaryocyte growth and proplatelet formation in mice by CLEC-2.
    Tamura S; Suzuki-Inoue K; Tsukiji N; Shirai T; Sasaki T; Osada M; Satoh K; Ozaki Y
    Blood; 2016 Mar; 127(13):1701-10. PubMed ID: 26796360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2.
    Herzog BH; Fu J; Wilson SJ; Hess PR; Sen A; McDaniel JM; Pan Y; Sheng M; Yago T; Silasi-Mansat R; McGee S; May F; Nieswandt B; Morris AJ; Lupu F; Coughlin SR; McEver RP; Chen H; Kahn ML; Xia L
    Nature; 2013 Oct; 502(7469):105-9. PubMed ID: 23995678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphenyl-tetrazol-propanamide Derivatives Act as Dual-Specific Antagonists of Platelet CLEC-2 and Glycoprotein VI.
    Watanabe N; Shinozaki Y; Ogiwara S; Miyagasako R; Sasaki A; Kato J; Suzuki Y; Fukunishi N; Okada Y; Saito T; Iida Y; Higashiseto M; Masuda H; Nagata E; Gotoh K; Amino M; Tsuji T; Morita S; Nakagawa Y; Hirayama N; Inokuchi S
    Thromb Haemost; 2024 Mar; 124(3):203-222. PubMed ID: 37967855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CLEC-2 stimulates IGF-1 secretion from podoplanin-positive stromal cells and positively regulates erythropoiesis in mice.
    Otake S; Sasaki T; Shirai T; Tsukiji N; Tamura S; Takano K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2021 Jun; 19(6):1572-1584. PubMed ID: 33774924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2.
    Tseng CP; Huang YL; Chang YW; Liao HR; Chen YL; Hsieh PW
    J Food Drug Anal; 2020 Jan; 28(1):115-123. PubMed ID: 31883599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood.
    Suzuki-Inoue K; Osada M; Ozaki Y
    J Thromb Haemost; 2017 Feb; 15(2):219-229. PubMed ID: 27960039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice.
    Shirai T; Inoue O; Tamura S; Tsukiji N; Sasaki T; Endo H; Satoh K; Osada M; Sato-Uchida H; Fujii H; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2017 Mar; 15(3):513-525. PubMed ID: 28028907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes.
    Tanaka K; Tanaka M; Watanabe N; Ito M; Pastan I; Koizumi M; Matsusaka T
    Sci Rep; 2022 Dec; 12(1):22356. PubMed ID: 36572741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells.
    Pollitt AY; Poulter NS; Gitz E; Navarro-Nuñez L; Wang YJ; Hughes CE; Thomas SG; Nieswandt B; Douglas MR; Owen DM; Jackson DG; Dustin ML; Watson SP
    J Biol Chem; 2014 Dec; 289(52):35695-710. PubMed ID: 25368330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.
    Suzuki-Inoue K
    Blood; 2019 Nov; 134(22):1912-1918. PubMed ID: 31778548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLEC-2-dependent platelet subendothelial accumulation by flow disturbance contributes to atherogenesis in mice.
    Tang C; Wang L; Sheng Y; Zheng Z; Xie Z; Wu F; You T; Ren L; Xia L; Ruan C; Zhu L
    Theranostics; 2021; 11(20):9791-9804. PubMed ID: 34815786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.